On March 22, Kangchen Pharmaceutical (603590) recently released its 2020 annual report, during which the company achieved operating income of 808,643,947.92 yuan, down 24.14% year-on-year; the net profit attributable to the shareholders of the listed company was 183,358,787.55 yuan, down 31.09% year-on-year.
Net cash flow from operating activities during the reporting period was RMB58,405,515.70 and net assets attributable to shareholders of the listed company as of the end of 2020 were RMB3,078,339,990.15.
The net profit attributable to the shareholders of the listed company decreased by 31.09% compared with the same period of the previous year, and the net profit attributable to the shareholders of the listed company after deducting non-recurring gains and losses decreased by 35.93% compared with the same period of the previous year, mainly due to the decrease in the company's sales revenue affected by the epidemic in the reporting period, and the net cash flow from operating activities decreased by 77.71% compared with the same period of the previous year, mainly due to the reduction of the company's sales revenue and payment collection affected by the epidemic in the reporting period.
Finance expenses for the period - 48,177,929.79 yuan, down 22.63% year-on-year. Investment income for the Period was RMB11,324,533.27, compared to RMB8,908,893.04 for the same period last year, an increase year-on-year.
The announcement shows that the remuneration of directors, supervisors and senior management during the reporting period totaled 5.3845 million yuan. Chairman Wang Xijuan did not receive remuneration in the company, president and director Liu Jianhua received a total of 604,900 yuan in pre-tax remuneration from the company, financial director Song Xiaomi received a total of 1.2677 million yuan in pre-tax remuneration from the company, and Tang Zhisong, secretary of the board of directors, received a total of 995,200 yuan in pre-tax remuneration from the company.
The announcement discloses that the profit distribution plan for the reporting period or the plan for the conversion of provident fund into equity capital deliberated by the board of directors: The company held the sixteenth meeting of the third board of directors on March 22, 2021, deliberated and passed the "2020 annual profit distribution plan", and agreed to distribute profits based on the number of shares payable on the record date of the company's implementation of the equity distribution in 2020 (the total share capital deducts the balance of the company's repurchased special account), and distributed a cash dividend of RMB3.50 (including tax) to all shareholders for every 10 shares. This plan has yet to be submitted to the General Meeting of Shareholders for consideration.
According to the data of the digging network, Kangchen Pharmaceutical is an innovative drug enterprise that adheres to the research and development of innovative drugs as the core, takes the clinical demand as the orientation, and integrates research and development, production and sales.
This article originated from the digging shell network
![Kangchen Pharmaceutical's core product revenue decreased by 25% Research and development expenses fell by 14.4% The single problem of products remains unsolved[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)